Home / Brands / PAI Holdings, LLC.
PAI Holdings, LLC. Recalls
7 recalls on record · April 1, 2020 to February 12, 2025 · Drugs
Recalls by year
20
21
25
Count of recall notices naming this brand, by the year the recall was announced. A quiet year is not proof of a safe year.
Also filed under
The recall feeds record what looks like the same company under more than one name:
February 12, 2025DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Guaifenesin and Codeine Phosphate Oral Solution USP, 100mg/10 mg per 5 mL, 16 fl oz (473 ml) bottles, PAI Pharmaceutical
Hazard: Superpotent; sodium benzoate preservative
August 18, 2021DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Ethosuximide Oral Solution USP 250 mg/5 mL, 16 fl oz (473 mL), Rx ONLY, Pharmaceutical Associates, Inc. Greenville, SC
Hazard: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
August 18, 2021DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Cimetidine Hydrochloride Oral Solution 300 mg/5 mL, 8 fl oz (237 mL) Rx ONLY, Pharmaceutical Associates, Inc. Greenvill
Hazard: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
August 18, 2021DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL)
Hazard: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
October 14, 2020DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Citalopram Oral Solution, USP 20 mg/10 mL, 10 mL unit dose cups, Rx Only, Mfg for: Pharmaceutical Associates, Inc. Green
Hazard: Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint
August 19, 2020DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl. oz. (473 mL), Rx only, Pharmaceutic
Hazard: Subpotent drug: Out of specification for assay at the 15-month test interval.
April 1, 2020DrugsFDA
PAI Holdings, LLC. dba Pharmaceutical Associates Inc recalls Nystatin Oral Suspension, USP, 100,000 units per mL, Cherry/Peppermint Flavor, 16 fl oz (473 mL) bottle, Rx ONLY, pai Ph
Hazard: SubPotent Drug: Low out-of-specification results for assay testing.